October 7, 2025 — San Antonio, Texas — Leads & Copy — BBG Advanced Therapies, a subsidiary of BioBridge Global, and CELLforCURE, part of SEQENS Group, have announced a partnership to support the development and large-scale production of Advanced Therapy Medicinal Products (ATMPs).
The collaboration creates a transatlantic connection, allowing U.S. companies to utilize CELLforCURE’s manufacturing capabilities in Europe, and European companies to benefit from BBG Advanced Therapies’ production capacities in the United States. The partnership provides enhanced global CDMO capacity and an integrated service network for ATMP developers.
BBG Advanced Therapies integrates cell and tissue expertise with biomanufacturing capabilities, adhering to FDA, EMA and PMDA regulations. CELLforCURE combines CDMO heritage and commercial manufacturing expertise from Phase I to full-scale production.
The collaboration aims to remove barriers in ATMPs manufacturing solutions, creating a fully scalable, global CDMO partnership between the USA and Europe to accelerate commercialization. The partnership enables therapy developers to scale rapidly, launch multinational trials, and reach patients more effectively, offering state-of-the-art GMP manufacturing space.
Mary Uhlig or SEQENS media team BioBridge Global or SEQENS – press@seqens.com 210-731-5519 mary.uhlig@biobridgeglobal.org
Source:
